SGP SGP
Company Profile ↓Company Overview
SGP (SGP) is a publicly traded company listed on with a market capitalization of $755.66M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 40.3%, reflecting efficient use of shareholder capital.
Carries low leverage with a debt-to-equity ratio of 0.01.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -10.30% |
| 6 Months: | - |
| 3 Months: | -2.99% |
| 1 Month: | +21.31% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)64.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 40.3%.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 7.75M | 7.42M | 13.63M | 15.41M |
| Operating Income | -7.75M | -7.42M | -13.63M | -15.41M |
| EBITDA | -7.65M | -7.30M | -13.41M | -15.09M |
| Interest Expense | - | - | - | - |
| Pretax Income | -8.40M | -8.82M | -12.56M | -13.82M |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -8.40M | -8.82M | -12.56M | -13.82M |
| Diluted EPS | - | -0.49 | - | -0.69 |
| R&D Expense | - | 6.05M | - | 8.54M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 14.23M | 27.06M | 41.45M |
| Operating Income | -14.23M | -27.06M | -41.45M |
| EBITDA | -14.11M | -26.79M | -40.84M |
| Interest Expense | - | - | - |
| Pretax Income | -13.32M | -29.16M | -39.87M |
| Tax Provision | 0 | 0 | 0 |
| Net Income | -13.32M | -29.16M | -39.87M |
| Diluted EPS | -1.17 | -1.62 | -1.25 |
| R&D Expense | - | 19.98M | 29.18M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 41.15M | 23.32M | 115.87M |
| Current Assets | 40.61M | 17.41M | 108.77M |
| Cash & Equivalents | 15.85M | 16.27M | 96.36M |
| Inventory | - | - | - |
| Receivables | 122.91K | 423.00K | 431.00K |
| Total Liabilities | 74.13M | 83.79M | 214.70M |
| Current Liabilities | 1.59M | 7.79M | 8.58M |
| Long Term Debt | - | - | - |
| Total Debt | 0 | 3.90M | 1.58M |
| Total Equity | -32.99M | -60.47M | -98.84M |
| Shares Outstanding | 31.91M | 31.91M | 31.91M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -12.28M | -22.03M | -32.70M |
| Investing Cash Flow | -20.49M | 22.26M | -11.79M |
| Financing Cash Flow | 39.77M | 185.00K | 124.58M |
| Capital Expenditure | -216.54K | -1.99M | -789.00K |
| Free Cash Flow | -12.49M | -24.02M | -33.49M |
| Net Change in Cash | 7.01M | 419.00K | 80.09M |
| Share Buybacks | - | 0 | 1.45M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | 40.4% | 48.2% | 40.3% |
| ROCE % | -36.0% | -174.3% | -38.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SGP
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as general counsel. Ms. Trev…
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as vice president, marketing. Mr. Pinder br…
SpyGlass Pharma to Participate in Upcoming Investor Conferences
ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participa…
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
Additional supportive reimbursement pathway for surgeons may enhance patient access to the BIM-IOL System upon potential commercializationALISO VIEJO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Ph…
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.Topline 12-month data from the BIM-IOL System Phase 1/2 trial demonstra…
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) that de…
SGP — Frequently Asked Questions
What is the current share price of SGP?
As of 2026-08-05 17:25 PDT, SGP trades at $23.68 on NASDAQ/NYSE. Its 52-week range is $17.56 to $29.68.
What is the market capitalisation of SGP?
SGP has a market capitalisation of $755.66M on NASDAQ/NYSE.
What is the P/E ratio of SGP?
SGP trades at a trailing price-to-earnings (P/E) ratio of -18.95. Its price-to-book (P/B) ratio is -7.65.
What is the return on equity (ROE) of SGP?
SGP has a return on equity (ROE) of 40.34%. Its return on capital employed (ROCE) is -38.64%.
Is SGP a good stock to buy?
This page provides a data-driven analysis of SGP, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.